MAP2K1 and melanoma: In 2020, Selumetinib (KOSELUGO, AstraZeneca), a highly specific MEKi, is approved for the treatment of pediatric children with neurofibromatosis type 1 (NP1) who have symptomatic, inoperable plexiform neurofibromas (PN).335 Selumetinib is also under evaluation for use in other cancers such as melanoma, gliomas, and non-small cell lung cancers, where MEK1/2 is overexpressed.336